PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Noble and Aptar Pharma launch connected medical device solution

Benefits of AdhereIT include improved drug management, enriched patient experiences and enhanced patient outcomes.

Noble and Aptar Pharma have launched AdhereIT — a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home.

The device is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

AdhereIT is part of the digital ecosystem that enables patients to gain control and confidence over their at-home drug delivery while easing the anxiety associated with self-injecting.

The device integrates with the existing software applications developed by the Digital Healthcare team at Aptar Pharma by pairing a patient’s autoinjector via Bluetooth technology to their mobile phone.

The device — available in two design options to accommodate dexterity for a one-handed or two-handed injection process — precisely detects an injection event and provides real-time visual, audio and haptic feedback about whether the injection was performed correctly.

The AdhereIT onboarding platform also allows HCPs to monitor their patients’ therapeutic performance via a smart analytical dashboard, providing valuable patient-specific adherence behavior information.

Noble developed AdhereIT in partnership with Aptar Pharma, who has made significant investments in digital healthcare over the past 3 years to actively develop a portfolio of disease management platforms and connected device solutions across dermal, pulmonary, nasal, ophthalmic and injectable routes of administration.

“Connected medical devices represent the future of healthcare for patients, pharmaceutical companies, health insurers and healthcare professionals, playing a vital role in the remote tracking and treatment of chronic illnesses, and delivering a range of benefits,” said Tim McLeroy, Noble’s Executive Director of Marketing & Patient Services.

He added: “The connectivity of digital technology solutions like AdhereIT also create market differentiation and enable value-based contracting for biopharmaceutical companies and medical device manufacturers to survive in a competitive and challenging marketplace.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026